{
    "clinical_study": {
        "@rank": "77262", 
        "acronym": "OPTIMIS", 
        "arm_group": [
            {
                "arm_group_label": "TACE + early Nexavar", 
                "description": "Patients with early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility to choose Sorafenib as the next treatment option (regardless of whether TACE treatment is continued or not)."
            }, 
            {
                "arm_group_label": "TACE without early Nexavar", 
                "description": "Patients without early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility not to choose Sorafenib as the next treatment option. This cohort also includes patients with TACE non-eligibility for whom the decision to treat with Sorafenib is made at a later point in time, patients who are never treated with Sorafenib as well as patients for whom another systemic cancer treatment has been chosen be the physician either at time of TACE non-eligibility or at a later point in time."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will collect data of patients who are treated with TACE followed by sorafenib for\n      hepatocellular carcinoma (HCC) or patients without Sorafenib after TACE. In contrast to a\n      prior observational study on sorafenib (GIDEON study), where pre-treatment with TACE was\n      documented retrospectively, this study will collect more detailed information about the TACE\n      treatment and the status of a patient when treatment with sorafenib is started."
        }, 
        "brief_title": "Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Hepatocellular", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histologically/cytologically documented or radiographically diagnosed\n             HCC. Radiographic diagnosis needs typical findings of HCC by radiographic method i.e.\n             on multi-dimensional dynamic CT, CT hepatic arteriography (CTHA)/CT arterial\n             portography (CTAP) or MRI.\n\n          -  Patients with BCLC (Barcelona clinic liver cancer staging) stage B or higher.\n\n          -  Patients in whom a decision to treat with TACE has been made at time of study\n             enrollment. Patients that have received one TACE in the past also can be enrolled, if\n             the TACE was done at the same site and all required data about such previous TACEs\n             are available. TACE includes both conventional TACE with lipidiol (or similar agents)\n             and chemotherapeutic agent(s) and TACE with DC Beads excluding TAE without\n             chemotherapeutic agent.\n\n          -  Patients with unresectable HCC (incurable with curative treatments including\n             resection or ablation or not eligible for resection or local ablation)\n\n          -  Patients must have signed an informed consent form\n\n          -  Patients must have a life expectancy of at least 8 weeks\n\n        Exclusion Criteria:\n\n          -  Patients who have received TACE in the past but the data about TACE required in this\n             protocol are not available\n\n          -  Patients who received any systemic anti-cancer therapy prior to the first TACE\n\n          -  Patients who are treated according to a trial protocol for intervention including a\n             locoregional therapy or systemic therapy\n\n          -  Hospice patients\n\n          -  All contra-indications according to the local marketing authorization should be\n             considered."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Female and male patients with a diagnosis of hepatocellular carcinoma (HCC) will be\n        enrolled in the participating study countries and sites during the enrollment period. All\n        treatment decisions prior inclusion of a patient as well as during the observation must be\n        made by the investigator based on his regular medical practice. Patients must give written\n        informed consent prior to documentation.\n\n        During the course of the study, patients will be assigned to one of the following cohorts\n        of special interest:\n\n          1. Patients with early start of sorafenib treatment\n\n          2. Patients without early start of sorafenib treatment."
            }
        }, 
        "enrollment": {
            "#text": "1670", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933945", 
            "org_study_id": "16560", 
            "secondary_id": "NX1301"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "TACE + early Nexavar", 
                    "TACE without early Nexavar"
                ], 
                "description": "First treatment for all patients included in the study", 
                "intervention_name": "TACE (transarterial chemoembolization)", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "TACE + early Nexavar", 
                "intervention_name": "Sorafenib (Nexavar, BAY43-9006)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Austria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Brazil"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Canada"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Denmark"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Egypt"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "France"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Greece"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Hong Kong"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Hungary"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "India"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Indonesia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Israel"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Kazakhstan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Mexico"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Netherlands"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Pakistan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Poland"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Russian Federation"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Singapore"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Slovakia"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Spain"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Sweden"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Switzerland"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Taiwan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Thailand"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Turkey"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many locations", 
                        "country": "Vietnam"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Brazil", 
                "Canada", 
                "China", 
                "Czech Republic", 
                "Denmark", 
                "Egypt", 
                "France", 
                "Greece", 
                "Hong Kong", 
                "Hungary", 
                "India", 
                "Indonesia", 
                "Israel", 
                "Japan", 
                "Kazakhstan", 
                "Korea, Republic of", 
                "Mexico", 
                "Netherlands", 
                "Pakistan", 
                "Poland", 
                "Russian Federation", 
                "Singapore", 
                "Slovakia", 
                "Spain", 
                "Sweden", 
                "Switzerland", 
                "Taiwan", 
                "Thailand", 
                "Turkey", 
                "Vietnam"
            ]
        }, 
        "number_of_groups": "2", 
        "official_title": "OPTIMIS - Outcomes of HCC Patients Treated With TACE Followed or Not Followed by Sorafenib and the Influence of Timing to Initiate Sorafenib", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Federal Office for Safety in Health Care", 
                "Canada: Ethics Committee", 
                "China: Ethics Committee", 
                "Denmark: Danish Health and Medicines Authority", 
                "Greece & Cyprus: National Organization of Drugs (EOF)", 
                "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines", 
                "Japan: Ministry of Health, Labor and Welfare", 
                "Kazakhstan and Mongolia: National Center for Expertise of Drugs, Medical Products and Equipment", 
                "Korea: Food and Drug Administration", 
                "Mexico: Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (COFEPRIS)", 
                "Pakistan: Ethics Committee", 
                "Singapore: Domain Specific Review Boards", 
                "Turkey: Ministry of Health", 
                "Sweden: Ethics Committee", 
                "Taiwan: Ethics Committee", 
                "Thailand: Republic of Turkey Ministry of Health General Directorate of Pharmaceuticals and Pharmacy", 
                "Turkey: Republic of Turkey Ministry of Health General Directorate of Pharmaceuticals and Pharmacy", 
                "Vietnam: Ministry of Health Ethics Committee", 
                "Egypt: Ministry of Health and Population-Central Directorate for research and Helath development"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Defined as time (in days) from time of TACE non-eligibility to death due to any cause. Patients lost to follow-up or alive at the end of the study will be censored at the last date known to be alive.", 
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933945"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival from initial TACE", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Progression-free survival from initial TACE", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Time to progression from initial TACE", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Tumor response according to mRECIST criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Duration of treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Number of patients with TEAEs (treatment emergent adverse events)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}